Background: Serum uric acid (sUA) control is of key relevance in tumor lysis syndrome (TLS) prevention as it correlates with both TLS and renal event risk. We sought to determine whether febuxostat fixed dose achieves a better sUA control than allopurinol while preserving renal function in TLS prevention.
(HM) [1, 2] . It encompasses metabolic derangements that predispose the patient to renal insufficiency, cardiac arrhythmias, neurological complications and potentially sudden death [2, 3] . The control of serum uric acid (sUA) level plays a key role in TLS prevention as urate triggers several mechanisms that lead to acute kidney injury [4] [5] [6] . Noteworthy, TLS guidelines consider the risk of developing TLS and renal events to be increased by 1.75-and 2.21-fold, respectively, for every mg/dl increase in sUA [2] . The current recommendations for TLS prophylaxis include the use of allopurinol or rasburicase in patients with intermediate or high-risk disease for developing TLS, respectively [3] . Allopurinol is a xanthine-oxidase (XO) inhibitor widely used to prevent cancer-related hyperuricemia for almost 50 years [7] . Though efficacious and safe, allopurinol requires 24-72 h to inhibit uric acid formation, lacks fixed posology and needs dose-adaption based on renal function [3, 8] . Rasburicase, a recombinant form of urate oxidase, is faster and more effective than allopurinol in controlling sUA level in cancer patients [8, 9] . However, due to cost-restrictions its availability is widely variable throughout the European Union (EU). Febuxostat is a potent, oral XO inhibitor approved in both the United States and the EU for the management of chronic hyperuricemia in gout, where it has demonstrated its superiority over allopurinol in decreasing sUA level [10, 11] ; its average cost in the EU (120 mg strength) is ∼0.91 Euros/tablet. Unlike allopurinol, the nonpurine structure of febuxostat prevents the inhibition of other enzymes involved in purine and pyrimidine metabolism and allows the inhibition of both the oxidized and reduced forms of XO, eventually resulting into a more potent and selective activity [12] . Febuxostat exhibits linear pharmacokinetics and the rate and extent of absorption are not substantially affected by age and gender. Noteworthy, no dose adjustment is necessary in patients with mild or moderate renal impairment, nor any of the drugdrug interaction studies conducted so far provided specific dosing recommendations [13] . In view of such profile, febuxostat was deemed suitable for development in TLS. Here, we present the results of the double-blind, randomized, phase III pivotal study comparing a fixed daily dose of febuxostat with allopurinol, administered at an adaptable daily dose, for TLS prevention in patients with HM at intermediate to high TLS risk grade.
patients and methods

study design
This multicenter, double-blind, randomized, parallel-group, comparative phase III pivotal study encompassed two treatment arms: febuxostat and allopurinol, either administered orally for 7-9 days. The primary objective was to compare the efficacy of febuxostat with allopurinol, in terms of sUA level control and preservation of renal function after 7 days of treatment starting 2 days before chemotherapy (CT) onset. The co-primary efficacy measures were area under the concentration-time curve over days 1-8 of sUA (AUC sUA [1] [2] [3] [4] [5] [6] [7] [8] ) and change in serum creatinine level, each evaluated from baseline (day 1) to the evaluation visit (day 8). Secondary objectives included treatment responder rate, where treatment response was the maintenance of sUA ≤7.5 mg/dl (treatment failure was two or more consecutive values of sUA missing or >7.5 mg/dl), incidence of laboratory TLS (LTLS) and clinical TLS (CTLS) defined as per Cairo and Bishop criteria [14] and safety. Secondary efficacy objectives were evaluated from the start of CT (day 3) to the evaluation visit (day 8). The study was conducted in 79 sites across 11 European countries and Brazil. A sample size of 340 patients was considered adequate to achieve 80% power, to demonstrate a benefit of febuxostat versus allopurinol of 15% decrease in AUC sUA1-8 and 13% increase in the mean serum creatinine.
patients
Patients provided fully informed, written consent before enrollment. The study was approved by local institutional review boards and conducted in accordance with Good Clinical Practice and the Helsinki Declaration of the World Medical Assembly. Eligible criteria included age ≥18 years, Eastern Cooperative Oncology Group performance status of 0-3, life expectancy of ≥1 month, sUA level <10 mg/dl at randomization, scheduled to receive first cytotoxic CT cycle (regardless of the line of treatment) because of HM at intermediate or high TLS risk as per TLS panel consensus [3] , candidate to allopurinol treatment or no access to rasburicase. Main exclusion criteria were uncontrolled ischemic heart disease or congestive heart failure, severe renal and/or hepatic insufficiency, presence of LTLS/CTLS at randomization, hypersensitivity to febuxostat or allopurinol (or respective excipients), treatment with any investigational drug or any urate-lowering therapy within 30 days before randomization or with mercaptopurine or azathioprine within 14 days before randomization.
study treatment and assessments
Patients stratified by TLS risk (intermediate or high) and baseline sUA levels (≤7.5 or >7.5 mg/dl) were randomized to either arm at a 1 : 1 ratio, using a randomized block design. Study treatment was blinded while daily dose depended on investigator's choice among low, standard and high containing either allopurinol 200, 300 and 600 mg, respectively, or fixed febuxostat 120 mg. CT was initiated 2 days after the first dose of urate-lowering treatment. Treatment duration was 7-9 days according to CT duration as per investigator's judgment. Adequate or increased hydration up to 3 l/m 2 /day was recommended according to TLS prophylaxis recommendations [3] . Randomization visit (day 1) assessments were considered as baseline; screening visit assessments, if carried out within 24 h before randomization, could be considered as baseline and not repeated. Samples for sUA and serum creatinine levels were collected at baseline and daily before study drug intake up to the evaluation visit (day 8). Treatment-emergent signs and symptoms (TESSs) reports and hematology and clinical chemistry data were collected throughout study treatment and on day 14. Central laboratory evaluation was used for primary efficacy measures and treatment responder rate, local laboratory evaluation was used for LTLS and CTLS incidence.
statistical analysis
Safety analysis was carried out for all patients who received at least one dose of study drug. Primary and secondary efficacy analyses were carried out on all randomized patients (intention-to-treat analysis). The two co-primary end points were analyzed through analysis of covariance (ANCOVA) in order to test the difference in treatment efficacy quantified by AUC sUA [1] [2] [3] [4] [5] [6] [7] [8] and change in serum creatinine level between treatment arms. All statistical tests were to be two-sided with a significance level of α = 0.05. The two ANCOVA models included the treatment and the two stratification factors (i.e. TLS risk and sUA levels) as covariates. The treatment responder rate was determined along with its 95% confidence interval (CI). Statistical comparison of treatment responder rates was conducted through the Wilson score CI for binomial variable and Wilson confidence limits were used [15] . One arm was considered superior to another if the lower one-sided 97.65% confidence limit of the difference in response rates between two arms was >0% (type I error rate = 4.695%). LTLS and CTLS incidence were summarized through descriptive statistics and compared using a χ 2 test. For safety assessments, descriptive statistics were used. (Table 1 ) with the exception of median lactate dehydrogenase (LDH) that was ∼24% higher in febuxostat arm (P = 0.0184). Overall, 82.1% of study patients were at intermediate TLS risk, 87.6% had a baseline sUA level ≤7.5 mg/dl and 82.7% were assigned to receive standard daily dose. All patients but one in febuxostat arm underwent CT during the study. Owing to missing values at baseline, one patient per arm was excluded from the analysis of AUC sUA [1] [2] [3] [4] [5] [6] [7] [8] ; for the same reason, two patients allocated to allopurinol were excluded from that of serum creatinine change.
sUA level control
The mean [±standard deviation (SD)] sUA AUC 1-8 was significantly lower for febuxostat than for allopurinol (514.0 ± 225.71 versus 708.0 ± 234.42 mg × h/dl; P < 0.0001). Mean (±SD) sUA at baseline showed no significant differences between febuxostat and allopurinol (5.6 ± 1.82 versus 5.8 ± 1.77 mg/dl; P = 0.3008), whereas it was significantly lower for febuxostat from the first 24 h of treatment throughout the whole treatment period up to the evaluation visit (P < 0.0001 at each time point; see Figure 1 ).
serum creatinine change over time
Mean (±SD) percent change in serum creatinine level from baseline to day 8 showed neither any positive change over time for febuxostat or allopurinol nor significant differences between The data were missing in one and three patients in febuxostat and allopurinol arm, respectively. The distribution of patients by dose level was consistently reported for either arm; however, the three dose levels were actually applied only to allopurinol, being febuxostat fixed 120 mg daily in any dose level. SD, standard deviation; LDH, lactate dehydrogenase; AL, acute leukemia; CLL, chronic lymphocytic leukemia; TLS, tumor lysis syndrome; sUA, serum uric acid.
Volume 
primary efficacy variables by subgroups
The results of the primary efficacy analysis were fully confirmed in subgroups of patients with different baseline characteristics in terms of sUA level, TLS risk grade, creatinine level, performance status score and malignant diagnosis ( Table 2) .
secondary efficacy analyses
No significant difference was found between treatment groups with respect to any of the secondary efficacy analysis. Treatment responder rate was 98% (95% CI 96% to 100%) for febuxostat and 96% (95% CI 93% to 99%) for allopurinol (P = 0.1993). LTLS and CTLS incidence was 8.1% versus 9.2% (P = 0.8488) and 1.7% versus 1.2% (P = 1.000) for febuxostat and allopurinol treatment arm, respectively.
safety
Overall, drug-related TESSs occurred only in 11 (6.4%) patients in each arm. The only system organ classes with at least 1% patients reporting drug-related TESSs were gastrointestinal disorders and investigations (Table 3) . Severe drug-related TESSs http://annonc.oxfordjournals.org/ occurred in two patients, both allocated to allopurinol. No drugrelated serious TESSs or deaths occurred. The most common TESSs across treatment arms, regardless of causality, pertained to the blood and lymphatic system (neutropenia, anemia, leukopenia, thrombocytopenia, febrile neutropenia), to the gastrointestinal system (nausea, diarrhea, constipation, vomiting), to investigations (platelet count decreased) and to the general disorders and administration site conditions (mucosal inflammation, pyrexia), reflecting the known common toxicities of concomitant CT. The most common serious TESSs across treatment groups, regardless of causality, were pneumonia (1.2%-2.9%) and febrile neutropenia (0.6%-1.7%). One patient in the febuxostat arm discontinued study treatment because of TESSs, namely hematuria and septic shock with a consecutive fatal outcome, which were unrelated to the study drug.
discussion
The sUA control is a key element in the prevention of TLS and renal events because the risk for TLS and renal events increases by 1.75-and 2.21-fold for every mg/dl increase in sUA, respectively [2] . Up to now allopurinol, which needs dose-adaption based on kidney function and rasburicase are the two available agents in the TLS prophylaxis. This large, phase III, registration study was designed to demonstrate the superiority of a fixed daily dose of febuxostat over allopurinol, administered at an Severe in intensity TESSs, treatment-emergent signs and symptoms; SOC, system organ class; PT, preferred term; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyltransferase.
adaptable daily dose, in patients with HM at risk for TLS. Febuxostat proved to be significantly superior over allopurinol in controlling sUA level throughout the whole treatment period (P < 0.0001). The higher efficacy of febuxostat in reducing the sUA exposure was moreover confirmed in subgroups of patients with different baseline sUA level, TLS risk grade, creatinine level, performance status and malignant disease (Table 2 ). In addition, since the first 24 h of treatment, febuxostat achieved a significantly higher sUA reduction at each time point compared with allopurinol ( Figure 1) . Noteworthy, although TLS risk categories were balanced between treatment arms following the stratification procedure, the febuxostat-treated population had a higher pretreatment LDH level (P = 0.0184) which might reflect a greater malignant disease burden and consequently enhance sUA increase soon after CT. Despite this, as previously mentioned febuxostat demonstrated its superiority over allopurinol since the first 24 h of treatment and this could be relevant for patients in urgent need of CT when rasburicase is unavailable. The serum creatinine percent change throughout the treatment period demonstrated that both treatments were able to prevent creatinine increase over time. In a previous study on pediatric patients with HM, allopurinol led to an 11% increase in serum creatinine but that study enrolled only patients at high TLS risk [9] . Conversely, in our study, the majority of patients were at intermediate risk. By starting the XO inhibition 2 days before CT onset in such a population, both treatments were able to prevent creatinine increase, with the advantage of a fixed daily dose for febuxostat. Treatment responder rate was high and comparable between the two treatments. Of note, our study defined treatment failure as two or more consecutive values of sUA missing or >7.5 mg/dl. Cortes et al. found an 11% treatment failure rate due to hyperuricemia following allopurinol in patients at TLS risk, but in that study a single sUA value >7.5 mg/dl was sufficient to determine treatment failure [8] . Overall, the incidence of LTLS and CTLS was small and comparable between treatment arms. In the study of Cortes et al., rasburicase achieved a lower LTLS incidence and a comparable CTLS incidence in respect of allopurinol alone, but ∼90% of patients were at high TLS risk grade. Interestingly, similarly to our study, all randomized trials of rasburicase published to date (two of which compared it with allopurinol) adopted a reduction in sUA exposure rather than in TLS incidence as the primary end point [8, 9, [16] [17] [18] [19] . Indeed, adequate hydration and allopurinol provide an effective benchmark for TLS prophylaxis, thus determining the need to use this recognized surrogate end point to design feasible trials in this setting. The present study encompassed a wide variability of HM, in terms of both type and line of treatment, as well as of CT regimens. In addition, increased hydration was recommended, but not systematically recorded among concomitant medications. On the one hand, such topics, moreover shared with previous randomized trials in TLS prophylaxis [8, 9] , are acknowledged as limitations to results interpretation, though partially contained by the one-to-one randomization ratio. On the other hand, they also reflect the actual clinical practice, thus adding at the same time some value to these trials. In conclusion, in this study, febuxostat 120 mg fixed daily dose demonstrated to be well tolerated and rapidly more effective than allopurinol in reducing sUA level, with a comparable prevention of creatinine increase over time in patients at intermediate to high TLS risk. Allopurinol is an efficacious, safe and cost-effective drug that so far has been the only oral agent approved to prevent cancer-related hyperuricemia and actually is the only TLS prophylaxis available in several European countries. However, based on the results of this trial, febuxostat has been recently approved in the EU for the prevention and treatment of hyperuricemia in adult patients undergoing CT for HM at intermediate to high TLS risk [20] , and may indeed represent a valid option in the TLS prophylaxis armamentarium, especially for patients in need of a fast sUA reduction. 
